Nuvation Bio Inc.
NUVBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Nuvation Bio Inc. (NUVB) is listed under Biotechnology. The company carries a $2.39B market cap, placing it firmly in the mid-cap category. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Market Cap
$2.39B
Beta
1.53
P/E (TTM)
—
P/E (Fwd)
-454.00
EPS (TTM)
$-0.44
EPS (Fwd)
$-0.01
ROE
-47.8%
ROA
-12.4%
Cash
$661.0M
Total Debt
$416.3M
Free CF
-$112.1M
52W Change
103.3%
Annual Financials
Cash vs Debt
Where NUVB stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, NUVB finished 23.65% above its 150-day moving average ($5.37) and 12.16% above its 200-day moving average ($5.92). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NUVB overbought or oversold?
At the September 2, 2026 close, NUVB's RSI(14) was 53.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $661.0M in cash and $416.3M in debt, NUVB maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$112.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -47.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 1.53 means NUVB is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing NUVB's risk profile alongside its fundamentals and technical indicators provides a more complete picture.